About Us

About Us

Using Cancer Against Itself

Our therapeutic hijacks the cancer cell and recruits cancer-causing transcription factors to drive a multimodal immunotherapy.

Team Members

Ariel Yusupov, Founder/CEO

MS in Biophysics, Georgetown University

MD candidate, NYMC

Dr. Mark N. Stein, MD

Columbia University Medical Center

Dr. Matthew Dallos, MD

Memorial Sloane Kettering Cancer Center

Dr. Jenny Zilberberg, PhD

Head of Research, Imvax, Inc.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Quick Links

Our Services

  • About us
  • Pipeline
  • Our Approach
  • Careers
  • Media
  • Contact Us

Social Links

Linkedin Instagram

Contact Us

* We never spam your email

ALLRIGHT RESERVED - Ariel Yusupov 2024

Ariel Yusupov has over a decade of experience in academia and industry, with expertise in prostate cancer, nucleic acid-based therapeutics, immunotherapy, and gene therapy. His industry experiences at Pfizer and Johnson and Johnson involved him leading development of nucleic acid-based therapeutics, AAV-based gene therapy, and CAR-T cell therapy from discovery to Phase III. At Pfizer, he was a foundational scientist on the mRNA vaccine discovery team. He then joined the Cell, Gene Therapy and Vaccines team at Johnson and Johnson to lead development of a self-amplifying RNA-based therapy for chronic hepatitis B, in addition to leading development efforts for the AAV-based gene therapy and the BCMA CAR-T programs. This experience, in combination of his over decade of prostate cancer research, has led him to pursue his own invention as the founder of FIG Therapeutics.